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Background: Urinary (U)-complement components have been detected in patients with proteinuric renal diseases,
and complement activation via the alternative pathway (AP) is believed to play a role in renal tubular damage. The
present study aimed to examine the regulation of complement AP activation in patients with renal tubular damage
by focusing on the balance between properdin (P) and factor H (fH).
Methods: In the in vivo studies, U concentrations of P, fH and membrane attack complex (MAC) were measured in
patients with renal diseases using an enzyme-linked immunosorbent assay (ELISA), and their relationships with the
clinical data were evaluated. In the in vitro studies, human proximal tubular epithelial cells (PTECs) were incubated
with normal human serum (NHS), P-depleted serum (PDS), purified P and/or fH. Changes in cell morphology and
phenotype were assessed by microscopy, real-time polymerase chain reaction (PCR), immunostaining and a cell
viability assay.
Results: The U-P, fH and MAC concentrations were significantly higher in patients with renal disease than in normal
controls and correlated with the U-protein and tubular damage markers. Furthermore, multivariate analysis revealed
a relationship between P levels and tubular damage markers. There were no significant changes in morphology
and mRNA expression in the AP components (P, fH, fB, C3, C5 and C9) after the addition of up to 25% NHS.
Dose-dependent depositions of P or fH were observed after the addition of P or fH on PTECs. Depositions of P were
not inhibited by fH in a mixture of a fixed concentration of P and a variable concentration of fH, and vice versa.
Preincubation with the fixed concentration of P before the addition of NHS or PDS increased the depositions of P,
C3 and MAC compared with incubation with intact NHS or intact PDS only; the depositions of C3 and MAC showed
a serum-dependent trend. Preincubation with P before NHS addition significantly suppressed cell viability without
causing morphological changes.
Conclusions: In the pathogenesis of renal tubular damage, P can directly bind to PTECs and may accelerate AP
activation by surpassing fH regulation.Background
Both experimental and clinical studies have shown that
proteinuria can directly lead to tubulointerstitial injury
[1,2]. Urinary (U)-complement components have been
detected in patients with proteinuric renal diseases [3-8],
and complement activation via the alternative pathway
(AP) may be involved in renal tubular damage [9-12].* Correspondence: yasu@juntendo.ac.jp
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article, unless otherwise stated.The AP is one of three complement activation pathways:
the classical pathway (CP), the lectin pathway (LP) and the
AP. The CP and LP are initiated by specific molecules,
namely antibodies and carbohydrates, respectively. The
AP remains continuously activated at low levels (the so-
called “tick over” effect) and acts indiscriminately on any
type of surface, i.e. native cells, tissues and foreign cells or
particles [13]. Therefore, the AP can be controlled by a
number of inhibitory regulators; however, there is only one
known positive regulator called properdin (P). AP activa-
tion is amplified after the formation of the C3 convertasetral Ltd. This is an Open Access article distributed under the terms of the
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it by 5–10 fold [14]. Factor H (fH), which is one of the
most important fluid phase inhibitory regulators of AP,
serves as a cofactor for factor I in the facilitation of the
cleavage of C3b to inactive C3b; it also accelerates the
decay of C3b, Bb and C3bBbP [13]. Inadequately con-
trolled AP activation has been implicated in the pathogen-
esis of different diseases. In addition, researchers have
recognized that mutated or defective fH may be associated
with atypical haemolytic uremic syndrome, dense deposit
disease and age-related macular degeneration [15].
Recent studies have shed new light on P, which can
also act as an initiator of direct complement activation
by recognizing and binding to specific target surfaces
such as apoptotic T cells [16] and proximal tubular epi-
thelial cells (PTECs) [9]; this mechanism has been re-
ferred to as the properdin-directed pathway (PDP) [17].
On the other hand, fH can also act as a surface-bound
regulator of AP and can bind to endothelial cells [18]
and PTECs [19]. P and fH are key counterpart regulator
proteins for AP, and interestingly, recent reports have
indicated that both can bind to renal PTECs [10,14,19].
Recent reports have also suggested that both P and fH
are involved in the pathogenesis of complement-mediated
renal tubular damage. However, most of the previous re-
ports were either research studies that evaluated U-
complement components in patients with a single renal
disease such as IgA nephropathy [3], membranous ne-
phropathy [4] and others or studies that evaluated either
U-P or U-fH in patients with proteinuric renal diseases
without examining the combination of P and fH in pa-
tients with a variety of renal diseases. In addition, super-
iority between P and fH in the AP activation of PTECs
remains unclear; the competitive binding of P and fH on
PTECs has not been fully studied.
In the present study, we planned in vivo and vitro studies
to examine the abovementioned issues. In the in vivo stud-
ies, we measured the U-complement components (P, fH
and MAC) in patients with various renal diseases and ex-
amined their relationships with the clinical data. In the
in vitro studies, we used cultured human PTECs to exam-
ine AP activation during renal tubular damage by focusing
on the competitive binding of P and fH and the enhance-




Sixty-three patients with renal diseases (35 males and 28
females; mean age, 42.3 ± 17.2 years) who were referred to
the Juntendo University Hospital between July 2010 and
November 2012 and 48 healthy volunteers (normal con-
trols; 34 males and 14 females; mean age, 34.1 ± 5.5 years)
with no history of renal dysfunction in annual periodicmedical check-ups were enrolled. Renal diseases included
the following: IgA nephropathy (IgAN; n = 25; males/fe-
males, 13/12; age, 38.0 ± 12.4 years), membranous nephrop-
athy (MN; n = 6, 3/3, 60.1 ± 13.7 years), non-IgA mesangial
proliferative glomerulonephritis (Non-IgAN; n = 5, 5/0,
44.4 ± 27.7 years), minimal change nephrotic syndrome
(MCNS; n = 5, 4/1, 46.2 ± 28.3 years), membranoproliferative
glomerulonephritis (MPGN; n = 2, 1/1, 48.0 ± 21.2 years),
focal segmental glomerulosclerosis (FSGS; n = 2, 2/0, 32.5 ±
21.9 years), tubulointerstitial nephritis (n = 1, 0/1, 33.0 years),
lupus nephritis (LN; n = 8, 5/3, 31.3 ± 6.9 years), diabetes
mellitus-induced nephropathy (DMN; n = 3, 3/0, 46.6 ±
25.1 years), nephrosclerosis (n = 2, 2/0, 57.0 ± 1.4 years),
Alport syndrome (n = 2, 0/2, 44.5 ± 2.1 years), light chain
deposition disease (n = 1, 1/0, 52.0 years) and amyloidosis
(n = 1, 1/0, 65.0 years). This study was approved by the Insti-
tutional Human Study ethics committee at Juntendo Univer-
sity, and written informed consent was obtained from
all participants. Each histological diagnosis was classified
through routine examination, including light microscopy
(LM) of renal biopsy specimens, and through the results of
immunoglobulin and complement deposition as assessed by
immunofluorescence (IF) and electron microscopy.
Laboratory data
Serum creatinine (S-Cre), U-creatinine (U-Cre), estimated
glomerular filtration rate (eGFR), U-protein, U-beta-2-mi-
croglobulin (U-B2MG) and U-N-acetyl-beta-D-glucosami-
nidase (U-NAG) levels were measured as part of routine
clinical analysis at the time of renal biopsy. Laboratory data
were collected in the central laboratory at the Juntendo
University Hospital.Measurement of P, fH and MAC in the urine
Urine samples were obtained and stored at −80°C before
use. U-concentrations of P, fH and MAC were measured
with commercially available ELISA kits [Human Proper-
din KIT and Human Factor H KIT, Hycult Biotech,
Uden, Netherlands and SC5b-9 (MAC) Plus EIA KIT,
Quidel, San Diego, CA, USA]. Absorbance at 450 nm
was determined using a microplate reader (SpectraMax
340, Molecular Devices, Sunnyvale, CA, USA).
In vitro studies
Blood samples and reagents
Normal human serum (NHS) was obtained from a
healthy volunteer. P-depleted human serum (PDS) and
purified P were purchased from CompTech (Tyler, Texas,
USA), while purified fH was purchased from Calbiochem
(Billerica, MA, USA). This study was also approved by the
Institutional Human Study ethics committee at Juntendo
University, and written informed consent was obtained
from this participant.
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The immortalized renal PTEC line human kidney-2 (HK-
2) was purchased from ATCC (Manassas, VA, USA).
PTECs were cultured until they were 90%–95% confluent
on the cover glass in 12-well culture plates for the IF stud-
ies and microscopic analysis, in a 100-mm dish for RNA
isolation and cDNA synthesis or in 96-well culture plates
for cell viability studies using a medium (DMEM; SIGMA,
St. Louis, MA, USA) containing 10% fetal calf serum. The
cells on the culture plates were incubated with an NHS-
containing medium, P-depleted serum (PDS), P and/or fH
for 3 h after incubation with a serum-free medium in the
CO2 incubator (5% CO2) at 37°C for 24 h, as described
previously [9].
Microscopic analysis
To determine the adequate conditions for the study and
assess the influence of complement activation and the
enhancement effects of P, PTECs were incubated with
different concentrations of NHS (5% and 25%) for 3 h
with or without preincubation with P (5 μg/mL) for 3 h.
The morphological changes in PTECs were observed by
LM (Keyence All-in-one fluorescence microscope BZ-
9000, Keyence, Osaka, Japan).
mRNA measurement of complement components
belonging to the AP
To further confirm adequate conditions for this study,
we examined the mRNA expression of the complement
components that belonged to the AP of PTECs. PTECs
were incubated with different concentrations of NHS
(5% and 25%) for 3 h. The RNA of PTECs was isolated
using an RNeasy Minikit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. For cDNA
synthesis, 4 μL of MTP, 2 μL of random primer and 2 μg
of RNA were incubated at 70°C for 3 min and directly
cooled. cDNA was synthesized by adding a mixture con-
taining 0.5 μL of M-MULVRT, 1 μL of RNase inhibitor
and 2 μL of 10× real-time polymerase chain reaction
(RT-PCR) buffer. The mixture was incubated at 42°C for
1 h. The samples were stored at −20°C. RT-PCR was per-
formed in a reaction of 18 μL containing 10 μL of SYBR
Green mastermix (Applied Biosystems, Foster City, CA,
USA), 1.6 μL of each primer, 4.8 μL of nuclease-free water
and 10 ng of cDNA. All samples were analysed in triplicate.
Thermal cycling was performed on an Applied Biosystems
7500 Fast RT-PCR system (Applied Biosystems), with a hot
start at 95°C for 20 s. Subsequently, 40 cycles were per-
formed, which included a denaturation step at 95°C for 3 s
followed by an annealing step at 60°C for 30 s. A last step
was included to detect the formation of primer dimers
(melting curve), starting with 15 s at 95°C followed by 60 s
at 60°C, 15 s at 95°C and 15 s at 60°C for one cycle.
cDNA-free double-distilled water was included as anegative control in each reaction. For quantification of the
PCR product, the samples were standardised with the PCR
product for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The primers were designed with Primer Express
software (Life Technologies, Carlsback, CA, USA). The
following primers were used: human P, forward 5′-GCAT
CCAGCACTGCCCCTTGAAA-3′ and reverse 5′-GGCA
CGGGTAGGATTAGGTCCACA-3′; human fH, forward
5′-TCCAGAAGGCACCCAGGCTATCTA-3′ and reverse
5′-CCACAGGGCCTTTTCTGACATTTCC-3′; human
factor B, forward 5′-CCATTTGTCTCCCCTGCACCGA-
3′ and 5′-GCAGCTCTTCCTTTTGTTGCTGGC-3′; hu-
man C3, forward 5′-ACGCGCAAGGGGATGTTCCA-3′
and reverse 5′-TCCCTGTTGGCTGGGATCGTGA-3′;
human C5, forward 5′-CTTGGGAGGCCAGTAGAG
GTGCT-3′ and reverse 5′-TGTACTGTAGCCAAGCC
ACTGCCAA-3′; human C9, forward 5′-ACACGACC
AGTTATGACCCAGAGC-3′ and reverse 5′-TGTGAC
CATTCACTCCAGGGGCT-3′.
P and fH binding assays
We incubated PTECs with variable concentrations of P
(0–10 μg/mL) or fH (0–400 μg/mL) for 3 h to examine
the binding of P or fH to PTECs. To evaluate the competi-
tive binding of P and fH, PTECs were also incubated with
a mixture of variable concentrations of P (0–10 μg/mL)
and fH (0–400 μg/mL) together for 3 h.
Complement AP activation assay
Next, we examined AP activation, the enhancement effect
of P and the dose-dependent effect of NHS on PTECs.
PTECs were incubated with NHS (5% or 25%) for 3 h with
or without preincubation with P at a fixed concentration
(5 μg/mL) for 3 h. For further confirmation of the en-
hancement effect of P, we incubated PTECs with PDS (5%
or 25%) for 3 h after preincubation with P (5 μg/mL).
IF studies for complement components on PTECs
The IF studies were executed as described previously [20].
After incubation, PTECs on the cover glass of the 12-well
culture plates were washed three times with 100 μL of
phosphate-buffered saline (PBS) at a pH of 7.4. PTECs
were then fixed with methanol for 5 min followed by
washing with PBS three times. Subsequently, the cells
were blocked with a blocking solution [1% bovine serum
albumin (BSA) in PBS] at room temperature for 30 min.
Indirect IF was used to determine P, fH and MAC. After
removal of the blocking BSA, PTECs were stained with
primary antibodies, i.e. mouse monoclonal anti-human P
antibody (Ab) at a 1:100 dilution, sheep polyclonal anti-
human fH Ab at a 1:50 dilution and rabbit polyclonal anti-
human C5b-9 (MAC) Ab at a 1:300 dilution (Abcam,
Cambridge, UK) for 1 h, respectively. After washing with
PBS three times, PTECs were stained with secondary
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Ab at a 1:100 dilution (Invitrogen, Carlsbad, CA, USA),
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-
sheep Ab at a 1:100 dilution (Abcam) and Alexa Fluor
488-conjugated donkey anti-rabbit Ab at a 1:250 dilution
(Invitorogen) for 1 h, respectively. Direct IF was used to de-
termine C3 deposition. After removal of the blocking BSA,
PTECs were stained with FITC-conjugated rabbit anti-
human C3c Ab at a 1:100 dilution (Dako, Glostrup,
Denmark) for 1 h. The nuclei were stained with DAPI
(4′,6-diamidine-2-phenylindole) at a 1:5000 dilution
(SIGMA) for 5 min. The slides were washed with PBS
several times and mounted. The deposition of comple-
ment components (P, fH, C3 and MAC) on PTECs was
observed by IF using a confocal microscope (Olympus
Viewer 1000, Olympus, Tokyo, Japan), and quantifica-
tion of the depositions was evaluated by FV 10–ASW
2.1 imaging software (Olympus).
Measurement of cell viability
We used the cell viability assay to assess the influence of
complement activation and the enhancement effect of P
on PTECs. PTECs were incubated with NHS (5% or 25%)
or a serum-free medium (control) for 3 h with or without
preincubation with P (5 μg/mL) for 3 h. Cell viability was
assessed using the Cell Proliferation Kit I (MTT; Roche
Applied Science, Penzberg, Germany) according to the
manufacturer’s instructions. Briefly, PTECs placed in 96-
well culture plates with 100 μL of culture medium
(DMEM) were incubated with 10 μL of the MTT [3-(4,5-
dimethylthiazol-2-2,5-yl)-2,5-diphenyltetrazolium bromide]
solution in a CO2 incubator (5% CO2) at 37°C for 4 h. After
this incubation, 100 μL of the solubilisation solution was
added to each well and incubated in the CO2 incubator (5%
CO2) at 37°C overnight. The spectrophotometrical absorb-
ance of the samples was measured using a microplate reader
(SpectraMax 340, Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
The data are expressed as means ± standard deviations
or standard errors. Comparisons among groups were
performed using the Mann–Whitney U test or one-way
ANOVA, and correlations among groups were evaluated
by Spearman’s analysis using Graphpad Prism 5 software
(Graphpad Software, La Jolla, CA, USA). Results of the
multivariate analysis were assessed through multiple re-
gression analysis using JMP software version 7 (SAS In-




In patients with renal diseases, the eGFR (mL/min/
1.73 m2) and U-protein (g/g Cre) levels were 81.81 ± 29.54and 2.13 ± 2.60, respectively. U-P, fH and MAC levels were
significantly higher in patients with renal disease than in
healthy controls, particularly U-P and MAC (p < 0.0001)
levels (Figure 1). U-P, fH and MAC levels were strongly
correlated with U-protein levels (p < 0.0001; Table 1). In
addition, there were significant correlations of U-P, fH and
MAC levels with the tubular damage markers U-B2MG
(versus P, p < 0.0001; versus fH, p = 0.0013; versus MAC,
p < 0.0005) and NAG (versus fH, p = 0.0158; versus MAC,
p = 0.0003; Table 1). Moreover, U-protein levels correlated
with U-B2MG (p = 0.001) and NAG (p < 0.0001) levels.
Furthermore, multivariate analysis revealed the relationship
between the U-complement components and tubular dam-
age markers. U-B2MG was correlated with U-P and NAG
was correlated with U-protein and U-P. U-P was the only
item that was correlated with both B2MG and NAG
(Table 2). Although patients with high U-protein levels, i.e.
those with DMN, amyloidosis, MCNS, FSGS and MPGN,
tended to have high U-P, fH and MAC levels, there was no
significant correlation with the pathological diagnosis.
In vitro studies
mRNA expressions of complement components belonging
to the AP of PTECs
There was no significant upregulation of mRNA expression
of the AP components, P, fH, fB, C3, C5 or C9 in PTECs
after the addition of up to 25% NHS for 3 h (Figure 2).
These results suggested that there was no significant over-
production of the complement AP components by PTECs
after the addition of up to 25% NHS.
Binding of P and fH on PTECs
Dose-dependent depositions of P and fH were observed
after the addition of P and fH. Depositions of P and fH
were observed at a concentration (P, ≥2 μg/mL; fH, ≥20 μg/
mL) lower than the physiological serum concentration
(P, 4–6 μg/mL; fH, 300–500 μg/mL; Figure 3) [21,22].
Competitive binding of P and fH on PTECs
When the concentrations of P were fixed (5 μg/mL) and
those of fH were variable (0–400 μg/mL), the depositions
of fH were dose-dependent, while those of P were not
inhibited by the variable concentrations of fH (Figure 4a).
On the other hand, when the concentrations of fH were
fixed (20 μg/mL) and those of P were variable (0–
10 μg/mL), the depositions of P were dose-dependent,
while those of fH were not inhibited by the variable
concentrations of P (Figure 4b).
Complement AP activation on PTECs in a serum-dependent
manner
Depositions of P, fH, C3 and MAC were observed after the
addition of both 5% and 25% NHS. Depositions of P, fH,
C3 and MAC were stronger with 25% NHS than with 5%
Figure 1 Urinary (U)-properdin (P), factor H (fH) and membrane attack complex (MAC) levels U-P (a), fH (b) and MAC (c) levels were
significantly higher in patients with renal diseases (n = 63) than in healthy controls (n = 48) as evaluated by ELISA. **p < 0.0001 versus
controls, *p < 0.05 versus controls.
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(5 μg/mL) before the addition of both 5% and 25% NHS in-
creased the depositions of P, C3 and MAC compared with
the addition of 5% and 25% intact NHS only (Figures 5a,b,
c,d); preincubation also increased the depositions of C3 and
MAC in a serum-dependent manner from 5% to 25% NHS.
Quantitative analysis was performed, and preincubation
with P before the addition of both 5% and 25% NHS signifi-
cantly increased (p < 0.001) the depositions of C3 and
MAC compared with the addition of 5% and 25% intact
NHS only (Figures 5e,f,g,h)Table 2 Association of U-P, fH, MAC and U-protein as
independent variables and U-B2MG and NAG as response
variables in patients with renal diseasesEnhancement effects of P for complement AP activation
on PTECs
Preincubation with P before the addition of 5% and 25%
PDS increased the depositions of P, C3 and MAC com-
pared with the addition of 5% and 25% intact PDS only
(Figures 6a,b,c,d). Depositions of P were slightly de-
tected with the addition of 25% PDS, but not 5% PDS.
Quantitative analysis was performed, and preincubation
with P before the addition of 5% and 25% PDS signifi-
cantly increased the depositions of C3 (5%, p < 0.001;Table 1 Correlations of U-P, fH and MAC with clinical
markers in patients with renal diseases
P fH MAC
r p r p r p
U-protein 0.756 <0.0001*** 0.525 <0.0001*** 0.577 <0.0001***
U-B2MG 0.675 <0.0001*** 0.401 0.0013** 0.431 <0.0005**
U-NAG 0.247 0.0502 0.303 0.0158* 0.443 0.0003**
eGFR −0.392 0.0015** −0.319 0.0106* −0.19 0.1348
Abbreviations: U, urinary; P, properdin; fH, factor H; MAC, membrane attack
complex; U-B2MG, U-beta-2-microglobulin; U-NAG, U-N-acetyl-β-D-glucosaminidase;
eGFR, estimated glomerular filtration rate.25%, p = 0.0079) and relatively increased the depositions
of MAC (p = 0.0556) compared with the addition of 5%
and 25% intact PDS only (Figures 6e,f,g,h).
Morphological changes and viability of PTECs
There were no significant morphological changes and
viability changes in PTECs after the addition of up to
25% NHS (Figure 7a,b,c,f ). Preincubation with P before
the addition of both 5% and 25% NHS significantly sup-
pressed the viability of PTECs compared with controls
and 5 and 25% intact NHS, without morphological
changes (Figure 7a,d,e,f ).
Discussion
This study aimed to clarify the role of AP regulation in
renal tubular damage through both in vivo and in vitro
examinations. First, we demonstrated that U-P, fH and




OR 95% CI p
U-B2MG U-P 5090.86 2305.25 to 7878.46 0.0006**
U-fH 253.11 −2353.81 to 1847.58 0.8101
U-MAC 1200.49 −1350 to 3751.50 0.3499
U-protein 912 −12353.81 to 1847.58 0.3986
U-NAG U-P −2.32 −4.22 to −0.43 0.0168*
U-fH 0.03 −1.47 to 1.55 0.9583
U-MAC 1.7 −0.15 to 3.55 0.0712
U-protein 3.15 1.58 to 4.71 0.0002**
Abbreviations: P, properdin; fH, factor H; MAC, membrane attack complex;
U-B2MG, U-beta-2-microglobulin; U-NAG, U-N-acetyl-β-D-glucosaminidase;
OR, odds ratio; CI, confidence interval.
Figure 2 mRNA expressions of complement components belonging to the alternative pathway (AP) by proximal tubular epithelial cells
(PTECs). PTECs were incubated with different concentrations of normal human serum (NHS; 5% or 25%) for 3 h. There were no significant
changes in the mRNA expression of AP components (P, fH, fB, C3, C5 and C9) after the addition of up to 25% NHS. (a) Serum-free medium,
(b) 5% NHS and (c) 25% NHS as evaluated by real-time polymerase chain reaction. Data are expressed as relative values compared with those for
control cells after the addition of a serum-free medium for 0 h. The results are expressed as means ± standard errors of values from four
independent experiments.
0µg/ml 2µg/ml 5µg/ml 10µg/ml
a Single addition of P
b Single addition of fH
0µg/ml 20µg/ml 100µg/ml 400µg/ml
Figure 3 Binding of properdin (P) and factor H (fH) on proximal tubular epithelial cells (PTECs). PTECs were incubated with variable
concentrations of P (0–10 μg/mL) or fH (0–400 μg/mL) for 3 h. Dose-dependent depositions of P (a) or fH (b) were observed by immunofluorescence
(IF). Depositions of P and fH were observed at a concentration (P, ≥2 μg/mL; fH, ≥20 μg/mL) lower than the physiological serum concentration
(P, 4–6 μg/mL; fH, 300–500 μg/mL). Original magnification: ×100. Arrow: depositions of P or fH.
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Figure 4 Competitive binding of properdin (P) and factor H (fH) on proximal tubular epithelial cells (PTECs). PTECs were incubated with
variable concentrations of a mixture of P and fH for 3 h. (a) In the mixture of P and fH (P concentration, 5 μg/mL; fH concentration, 0–400 μg/mL), the
depositions of fH were increased in a dose-dependent manner, while those of P remained unchanged, as observed by IF. (b) In the mixture of P and
fH (fH concentration, 20 μg/mL; P, 0–10 μg/mL), the depositions of P were increased in a dose-dependent manner, while those of fH remained
unchanged. Original magnification: ×100. Arrow: depositions of P or fH.
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correlated with U-protein levels and tubular damage
markers. In addition, U-protein levels were correlated
with the tubular damage markers, and the U-P, fH and
MAC levels were independent of the histological diag-
nosis, so that the filtered plasma protein through glom-
erular barrier impacted as an important causative factor
in renal tubular damage [2,9,23,24]. Even in a patient
with MCNS who had decreased renal function (eGFR:
60.4 mL/min), there was a tendency of high levels of U-
tubular damage markers, B2MG 9014.28 ng/mg Cre (all pa-
tients: 1176 ± 3113) and NAG 5.41 U/mg Cre (all patients:
1.57 ± 2.08), U-protein 10.38 g/g Cre and U-complement
components, U-P 44.10 ng/mg Cre, and U-fH 254.22 ng/
mg Cre and U-MAC 62.59 ng/mg Cre. Although there
were no high levels of tubular damage markers and U-complement components in patients without decreased
eGFR in MCNS, these results suggested that relationships
among high levels of U-protein, U-complement compo-
nents and U-tubular damage markers existed, even in
MCNS patients. Therefore, as U-complement components
and tubular damage markers increase in patients with
MCNS and advanced renal dysfunction, the levels of U-
complement components and tubular damage markers
may correlate with the levels of U-protein. Furthermore,
multivariable analysis revealed that only U-P was corre-
lated with both tubular damage markers, B2MG and
NAG. In the context of renal disease, this study represents
the first analysis, as per our knowledge, to clarify the role
of AP regulation by measuring the combination of U-P, fH
and MAC in the same samples from patients with various
renal diseases.
fH C3 MACP
































a Addition of 5%Normal human serum (NHS)
b Addition of 5%NHS after incubation with P
c Addition of 25%NHS












p < 0.001 p < 0.001
p < 0.001 p < 0.001
Figure 5 Complement alternative pathway (AP) activation on proximal tubular epithelial cells (PTECs). PTECs were incubated with
different concentrations of normal human serum (NHS; 5% or 25%) for 3 h. Depositions of properdin (P), factor H (fH), C3 and membrane attack
complex (MAC) with 25% NHS (c) were stronger than those with 5% NHS (a), as observed by immunofluorescence (IF). Preincubation with P
(5 μg/mL) for 3 h before the addition of both 5% (b) and 25% (d) NHS increased the depositions of P, C3 and MAC compared with those with
5% (a) and 25% (c) intact NHS. Quantitative analysis was performed, and preincubation with P before the addition of both 5% and 25% NHS
significantly increased depositions of C3 (e, g) and MAC (f, h) (**p < 0.001) compared with the addition of 5% and 25% intact NHS only. Results are
expressed as means ± standard errors of values from five representative lesions. Original magnification: ×100 Arrow: depositions of P, fH, C3 or MAC.
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http://www.biomedcentral.com/1471-2369/15/82The question arises whether these U-complement
components play a crucial role in renal tubular damage.
We examined complement AP activation on PTECs and
could delineate a delicate balance between P and fH.
From the single addition of P or fH, we could confirm
dose-dependent depositions of P and fH on PTECs
[14,19,23]. Zaferani et al. [14] suggested that P could
bind dose-dependently to heparan sulfate proteoglycan
(HSPG), which was thought to be one of the binding
sites on PTECs. They also suggested [23] that fH could
bind dose-dependently to HSPG and that P and fH
could bind to different epitopes of HSPG on PTECs.
Our results support these previous reports and indi-
cated that P and fH could bind dose-dependently toPTECs. Although the depositions of fH were observed in a
concentration (≥20 μg/mL) lower than the physiological
serum concentration of fH (300–500 μg/mL), the bindings
of P and fH are thought to be non-competitive in this ex-
periment. Unfortunately, the individual binding site on
PTECs could not be identified in this experiment, but it
does suggest that the binding of fH does not have enough
power to prevent the binding of P on PTECs.
We then recaptured the activation of complement AP on
PTECs. NHS was used as a source of complements and a
mimic of filtered plasma protein through the glomerular
barrier. The depositions of P, fH, C3 and MAC on PTECs
were observed to be dose-dependent of NHS [9,25]. Next,
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Figure 6 Enhancement effect of properdin (P) in complement alternative pathway (AP) activation on proximal tubular epithelial cells
(PTECs), PTECs were incubated with P-depleted serum (PDS; 5% or 25%) for 3 h. Preincubation with P (5 μg/mL) for 3 h before the
addition of PDS increased the depositions of P, C3 and MAC (b, d) compared with the addition of intact PDS only (a, c). Depositions of P were
slightly detected with the addition of 25% PDS, but not 5% PDS. Quantitative analysis was performed, and preincubation with P before the
addition of PDS significantly increased the depositions of C3 (e, g) (5% PDS, **p < 0.001; 25% PDS, *p = 0.0079) and relatively increased the
depositions of MAC (p = 0.0556) (f, h) compared with the addition of intact PDS only. Results are expressed as means ± standard errors of values
from five representative lesions. Original magnification: ×100. Arrow: depositions of P, fH, C3 or MAC.
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http://www.biomedcentral.com/1471-2369/15/82on PTECs, we preincubated PTECs with P before the
addition of NHS. Preincubation with the fixed concentra-
tion of P before the addition of NHS increased not only
the depositions of P but also those of C3 and MAC com-
pared with controls; preincubation also increased the de-
positions of C3 and MAC in a serum-dependent manner
from 5% to 25% NHS. Gaarkeuken et al. [9] also reported
that the filtered P may bind to PTECs and act as a focal
point for AP activation. In that report, P could be detected
along the brush border of the proximal tubules in the pa-
tients with MN, but it was not detected in the tubules of
healthy kidney tissues (pretransplant renal biopsies of liv-
ing kidney donors). Additional P was shown to increase
the depositions of C3 and MAC on PTECs in a P dose-dependent manner before incubation with 5% NHS. These
findings could add new insight to the previous reports by
suggesting that PTEC could initiate complement activa-
tion in a serum-dependent manner, with pre-exposure to
a physiological concentration of P.
We previously focused on the importance of PDP acti-
vation in the pathogenesis of LN and reported that PDP
activation in the glomeruli may lead to the early onset and
progression of LN and reflect disease activity [26]. In this
study, we also confirmed that preincubation with P before
the addition of PDS increased not only the deposition of P
but also the deposition of C3, while it relatively increased
the deposition of MAC; it was also suggested that P may
act as an enhancer of complement AP activation referred
a Serum free
with P with P
c 25%NHS b 5%NHS
e 25%NHSd 5%NHS  
f Viability
Figure 7 Morphological changes and viability of proximal tubular epithelial cells (PTECs). PTECs were incubated with normal human serum
(NHS; 5% or 25%) or serum-free medium (controls) for 3 h with or without preincubation with P (5 μg/mL) for 3 h. There were no significant morphological
changes in PTECs after the addition of up to 25% NHS. Preincubation with P before the addition of both 5% and 25% NHS did not cause morphological
changes in PTECs. (a) Serum-free medium (control), (b) 5% NHS, (c) 25% NHS, (d) 5% NHS with preincubation with P and (e) 25% NHS with preincubation
with P, as observed by a microscope. Pictures are representative of four-cell culture plates. Original magnification: ×50. There were no significant changes
in the viability of PTECs after the addition of 5% and 25% NHS (f). Preincubation with P before the addition of both 5% and 25% NHS significantly
suppressed the viability of PTECs compared with controls and 5% and 25% intact NHS (f) (**p< 0.01, *p< 0.05). Results are expressed as means ± standard
errors of values from eight independent experiments.
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http://www.biomedcentral.com/1471-2369/15/82to as PDP activation [17]. A similar result was confirmed
using flow cytometry in a previous report [9], where add-
itional P restored complement activation of PDS on PTECs.
We unexpectedly detected slight P staining on PTECs incu-
bated with 25% PDS, but not 5% PDS. We considered the
possibility that PDS was not completely depleted of P in the
serum and that even a very small amount of P could bind
to PTECs and activate AP and PDP, leading to the depos-
ition of MAC. We could confirm that 5.77 ng/mL of P was
present in the 25% PDS by ELISA (physiological serum
concentration of P: 4–6 μg/mL).
In our study, although the activation of AP was seem-
ingly ineffective in morphology, a functional effect was ob-
served. After the addition of NHS to PTECs, cell viability
was not significantly suppressed; however, preincubation
with P before the addition of NHS significantly suppressed
viability without causing morphological changes. Although
diverse factors affected cell viability [1], the changes in
this experiment were thought to reflect one possible
result of complement AP activation enhanced by P.
Therefore, we demonstrated the relationship between
AP activation enhanced by P and tubular damage in ex-
perimental situations.While there are numerous reports, including this study,
that support the role of P in AP complement-mediated
renal tubular damage, P-targeting therapy has also been
evaluated [11,27,28]. P blockade may be a logical thera-
peutic target, and the accumulation of further research is
required to decrease renal tubular damage.Conclusions
In the pathogenesis of renal tubular damage, P can bind
directly to PTECs and may play a significant role in
renal tubular damage by accelerating complement AP
activation and surpassing fH regulation.Competing interests
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